Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CardioKinetix Starts China Trial of Heart Failure Device

publication date: Oct 24, 2014
CardioKinetix of California has enrolled the first ten patients in a China clinical trial of its first-in-class, minimally invasive medical device to treat heart failure. Following a heart attack, many patients suffer from shortness of breath because their hearts have become enlarged, reducing output. CardioKinetix's Parachute® Ventricular Partitioning Device, inserted in the left ventricle via the femoral artery, partitions off the non-working section of the heart. The first China patients have been enrolled at Beijing's Peking University and Fu Wai Hospitals and at Shanghai Tenth People’s Hospital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital